QSAM Biosciences Inc., a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®), for the treatment of bone cancer and related diseases, recently announced that the first patient has begun to undergo treatment in its clinical trial evaluating CycloSam® in patients with metastatic bone cancer.
QSAM
previously announced the clearance of its IND by the U.S. Food and Drug
Administration (FDA) and the activation of clinical trial sites in its
multi-center clinical trial for patients with bone cancer, including cancer
that has metastasized from the lung, breast or prostate. The study is a Phase 1
open-label, dose-escalation trial to evaluate the safety, tolerability,
dosimetry, and preliminary efficacy of CycloSam®.
To
read more please visit:
Source: QSAM Biosciences